UT-MD Anderson Cancer Center: Dual Immunotherapy Plus Chemotherapy Before Surgery Improves Patient Outcomes in Operable Lung Cancer
March 17, 2023
March 17, 2023
HOUSTON, Texas, March 17 (TNSjou) -- The University of Texas's MD Anderson Cancer Center issued the following news release on March 16, 2023:
* * *
NEOSTAR Phase II platform trial demonstrates neoadjuvant immunotherapy combinations can enhance treatment responses in operable NSCLC
* * *
In a Phase II trial led by researchers from The University of Texas MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant, or pre-surgical, combination . . .
* * *
NEOSTAR Phase II platform trial demonstrates neoadjuvant immunotherapy combinations can enhance treatment responses in operable NSCLC
* * *
In a Phase II trial led by researchers from The University of Texas MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant, or pre-surgical, combination . . .